The emerging therapeutic role of mesenchymal stem cells in anthracycline-induced cardiotoxicity.

Huanrong Lan, Qi Xue, Yuyao Liu, Ketao Jin, Xingliang Fang, Hong Shao

Cell and tissue research 2021 Apr

filter terms:

Mesenchymal stem cell (MSC)-based tissue regeneration therapy has been extensively investigated for cardiac regeneration over the past two decades. Numerous animal and clinical investigations demonstrated the efficacy of various types of MSCs towards myocardial protection and restoration against anthracycline-induced cardiotoxicity (AIC). It has been established that local or systemic administration of MSCs considerably improved the cardiac function, while ameliorating inflammatory responses and myocardial fibrosis. Several factors influence the outcomes of MSC treatment for AIC, including MSC types, dosages, and routes and duration of administration. In this review, we discuss the recent (from 2015 to 2020) experimental and clinical research on the preventive and regeneration efficacy of different types of MSCs (with or without supporting agents) against AIC, as well as the key factors responsible for MSC-mediated cardiac repair. In addition, challenges and future perspectives of MSC-based cardiac regeneration therapy are also outlined.

Citation

Huanrong Lan, Qi Xue, Yuyao Liu, Ketao Jin, Xingliang Fang, Hong Shao. The emerging therapeutic role of mesenchymal stem cells in anthracycline-induced cardiotoxicity. Cell and tissue research. 2021 Apr;384(1):1-12